Gantenerumab reduces amyloid-β plaques in patients with prodromal to moderate Alzheimer’s disease: a PET substudy interim analysis

Gantenerumab reduces amyloid-β plaques in patients with prodromal to moderate Alzheimer’s disease: a PET substudy interim analysis

Abstract Background We previously investigated low doses (105 or 225 mg) of gantenerumab, a fully human monoclonal antibody that binds and removes aggregated amyloid-β by Fc receptor-mediated phagocytosis, in the SCarlet RoAD (SR) and Marguerite RoAD (MR) phase 3 trials. Several lines of evidence su...

Full description

Bibliographic Details
Main Authors: Gregory Klein, Paul Delmar, Nicola Voyle, Sunita Rehal, Carsten Hofmann, Danielle Abi-Saab, Mirjana Andjelkovic, Smiljana Ristic, Guoqiao Wang, Randall Bateman, Geoffrey A. Kerchner, Monika Baudler, Paulo Fontoura, Rachelle Doody
Format: Article
Language:English
Published: BMC 2019-12-01
Series:Alzheimer’s Research & Therapy
Subjects:
Alzheimer’s disease
Amyloid-β plaque
Centiloid
Disease-modification therapies
Gantenerumab
Florbetapir
Online Access:https://doi.org/10.1186/s13195-019-0559-z

Internet

https://doi.org/10.1186/s13195-019-0559-z

Similar Items